APA (7th ed.) Citation

Gatlik, E., Mehes, B., Voltz, E., Sommer, U., Tritto, E., Lestini, G., . . . Junge, G. (2024). First‐in‐human safety, tolerability, and pharmacokinetic results of DFV890, an oral low‐molecular‐weight NLRP3 inhibitor. CTS: Clinical & Translational Science, 17(5), 1. https://doi.org/10.1111/cts.13789

Chicago Style (17th ed.) Citation

Gatlik, Ewa, et al. "First‐in‐human Safety, Tolerability, and Pharmacokinetic Results of DFV890, an Oral Low‐molecular‐weight NLRP3 Inhibitor." CTS: Clinical & Translational Science 17, no. 5 (2024): 1. https://doi.org/10.1111/cts.13789.

MLA (9th ed.) Citation

Gatlik, Ewa, et al. "First‐in‐human Safety, Tolerability, and Pharmacokinetic Results of DFV890, an Oral Low‐molecular‐weight NLRP3 Inhibitor." CTS: Clinical & Translational Science, vol. 17, no. 5, 2024, p. 1, https://doi.org/10.1111/cts.13789.